Emerging molecular targets for anti-proliferative strategies in pulmonary arterial hypertension

Handbook of Experimental Pharmacology

Volumn 218, Issue , 2013, Pages 409-436

  Tu, Ly ^a,b   Guignabert, Christophe ^a,b  

^a Universite Paris Sud   (France)

^b UNIVERSITÉ PARIS SACLAY   (France)

Author keywords

Antiproliferative compounds; Growth factors; Pulmonary hypertension; Pulmonary vascular remodeling; Signal transduction

Indexed keywords

ANGIOTENSIN II; BONE MORPHOGENETIC PROTEIN RECEPTOR 2; CONNECTIVE TISSUE GROWTH FACTOR; EPIDERMAL GROWTH FACTOR; FIBROBLAST GROWTH FACTOR; JANUS KINASE; MAMMALIAN TARGET OF RAPAMYCIN; NERVE GROWTH FACTOR; PLACENTAL GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR; PROTEIN KINASE B; RHO KINASE; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; SCATTER FACTOR; SEROTONIN RECEPTOR; SOMATOMEDIN; STAT PROTEIN; VASCULOTROPIN;

AEROBIC METABOLISM; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; BLOOD VESSEL OCCLUSION; CELL PROLIFERATION; CLINICAL EFFECTIVENESS; EXTRACELLULAR MATRIX; HOMEOSTASIS; HUMAN; LUNG ARTERY PRESSURE; LUNG VASCULAR RESISTANCE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN TARGETING; PULMONARY HYPERTENSION; PULMONARY VASCULAR OBSTRUCTION; SIGNAL TRANSDUCTION; THROMBOSIS; VASOCONSTRICTION; VASODILATATION;

ANIMALS; CELL PROLIFERATION; HUMANS; HYPERTENSION, PULMONARY; PROTEIN KINASE INHIBITORS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, FIBROBLAST GROWTH FACTOR; RECEPTORS, PLATELET-DERIVED GROWTH FACTOR; SEROTONIN ANTAGONISTS;

EID: 84888817021     PISSN: 01712004     EISSN: 18650325     Source Type: Book Series    
DOI: 10.1007/978-3-642-38664-0_17     Document Type: Article

References (200)

1. Abe K, Shimokawa H et al (2004) Long-term treatment with a Rho-kinase inhibitor improves monocrotaline-induced fatal pulmonary hypertension in rats. Circ Res 94(3):385-393
2. Abenhaim L, Moride Y et al (1996) Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International Primary Pulmonary Hypertension Study Group. N Engl J Med 335(9):609-616
3. Arcot SS, Fagerland JA et al (1995) Basic fibroblast growth factor alterations during development of monocrotaline-induced pulmonary hypertension in rats. Growth Factors 12(2):121-130
4. Balasubramaniam V, Le Cras TD et al (2003) Role of platelet-derived growth factor in vascular remodeling during pulmonary hypertension in the ovine fetus. Am J Physiol Lung Cell Mol Physiol 284(5):L826-L833
5. Baudhuin LM, Jiang Y et al (2004) S1P3-mediated Akt activation and cross-talk with plateletderived growth factor receptor (PDGFR). FASEB J 18(2):341-343
6. Benezra M, Vlodavsky I et al (1993) Thrombin-induced release of active basic fibroblast growth factor-heparan sulfate complexes from subendothelial extracellular matrix. Blood 81(12):3324-3331
7. Benisty JI, McLaughlin VV et al (2004) Elevated basic fibroblast growth factor levels in patients with pulmonary arterial hypertension. Chest 126(4):1255-1261
8. Berk BC (2001) Vascular smooth muscle growth: Autocrine growth mechanisms. Physiol Rev 81(3):999-1030
9. Blanpain C, Le Poul E et al (2003) Serotonin 5-HT(2B) receptor loss of function mutation in a patient with fenfluramine-associated primary pulmonary hypertension. Cardiovasc Res 60(3):518-528
10. Bonnet S, Michelakis ED et al (2006) An abnormal mitochondrial-hypoxia inducible factor-1alpha-Kv channel pathway disrupts oxygen sensing and triggers pulmonary arterial hypertension in fawn hooded rats: Similarities to human pulmonary arterial hypertension. Circulation 113(22):2630-2641
11. Brenner B, Harney JT et al (2007) Plasma serotonin levels and the platelet serotonin transporter. J Neurochem 102(1):206-215
12. Brenot F, Herve P et al (1993) Primary pulmonary hypertension and fenfluramine use. Br Heart J 70(6):537-541
13. Breuer J, Georgaraki A et al (1996) Increased turnover of serotonin in children with pulmonary hypertension secondary to congenital heart disease. Pediatr Cardiol 17(4):214-219
14. Buczek-Thomas JA, Nugent MA (1999) Elastase-mediated release of heparan sulfate proteoglycans from pulmonary fibroblast cultures. A mechanism for basic fibroblast growth factor (bFGF) release and attenuation of bfgf binding following elastase-induced injury. J Biol Chem 274(35):25167-25172
15. Callebert J, Esteve JM et al (2006) Evidence for a control of plasma serotonin levels by 5-hydroxytryptamine(2B) receptors in mice. J Pharmacol Exp Ther 317(2):724-731
16. Campbell AI, Zhao Y et al (2001) Cell-based gene transfer of vascular endothelial growth factor attenuates monocrotaline-induced pulmonary hypertension. Circulation 104(18):2242-2248
17. Christ G, Graf S et al (2001) Impairment of the plasmin activation system in primary pulmonary hypertension: Evidence for gender differences. Thromb Haemost 86(2):557-562
18. Christou H, Yoshida A et al (1998) Increased vascular endothelial growth factor production in the lungs of rats with hypoxia-induced pulmonary hypertension. Am J Respir Cell Mol Biol 18(6):768-776
19. Ciccolini F, Svendsen CN (1998) Fibroblast growth factor 2 (FGF-2) promotes acquisition of epidermal growth factor (EGF) responsiveness in mouse striatal precursor cells: Identification of neural precursors responding to both EGF and FGF-2. J Neurosci 18(19):7869-7880
20. Ciuclan L, Bonneau O et al (2011) A novel murine model of severe pulmonary arterial hypertension. Am J Respir Crit Care Med 184(10):1171-1182
21. Cogolludo A, Moreno L et al (2006) Serotonin inhibits voltage-gated K+ currents in pulmonary artery smooth muscle cells: Role of 5-HT2A receptors, caveolin-1, and KV1.5 channel internalization. Circ Res 98(7):931-938
22. Cool CD, Kennedy D et al (1997) Pathogenesis and evolution of plexiform lesions in pulmonary hypertension associated with scleroderma and human immunodeficiency virus infection. Hum Pathol 28(4):434-442
23. Courboulin A, Paulin R et al (2011) Role for miR-204 in human pulmonary arterial hypertension. J Exp Med 208(3):535-548
24. Courboulin A, Barrier M et al (2012) Plumbagin reverses proliferation and resistance to apoptosis in experimental PAH. Eur Respir J 40(3):618-629
25. Cowan KN, Jones PL et al (1999) Regression of hypertrophied rat pulmonary arteries in organ culture is associated with suppression of proteolytic activity, inhibition of tenascin-C, and smooth muscle cell apoptosis. Circ Res 84(10):1223-1233
26. Cowan KN, Heilbut A et al (2000a) Complete reversal of fatal pulmonary hypertension in rats by a serine elastase inhibitor. Nat Med 6(6):698-702
27. Cowan KN, Jones PL et al (2000b) Elastase and matrix metalloproteinase inhibitors induce regression, and tenascin-C antisense prevents progression, of vascular disease. J Clin Invest 105(1):21-34
28. Dahal BK, Cornitescu T et al (2010) Role of epidermal growth factor inhibition in experimental pulmonary hypertension. Am J Respir Crit Care Med 181(2):158-167
29. Dann SG, Selvaraj A et al (2007) mTOR Complex1-S6K1 signaling: At the crossroads of obesity, diabetes and cancer. Trends Mol Med 13(6):252-259
30. de Man FS, Tu L et al (2012) Dysregulated renin-angiotensin-aldosterone system contributes to pulmonary arterial hypertension. Am J Respir Crit Care Med 186(8):780-789
31. Dimmeler S, Zeiher AM (1999) Nitric oxide-an endothelial cell survival factor. Cell Death Differ 6(10):964-968
32. Ding W, Shi W et al (2007) Sprouty2 downregulation plays a pivotal role in mediating crosstalk between TGF-beta1 signaling and EGF as well as FGF receptor tyrosine kinase-ERK pathways in mesenchymal cells. J Cell Physiol 212(3):796-806
33. Dorfmuller P, Perros F et al (2003) Inflammation in pulmonary arterial hypertension. Eur Respir J 22(2):358-363
34. Douglas JG, Munro JF et al (1981) Pulmonary hypertension and fenfluramine. Br Med J (Clin Res Ed) 283(6296):881-883
35. Du L, Sullivan CC et al (2003) Signaling molecules in nonfamilial pulmonary hypertension. N Engl J Med 348(6):500-509
36. Dumitrascu R, Kulcke C et al (2011) Terguride ameliorates monocrotaline induced pulmonary hypertension in rats. Eur Respir J 37(5):1104-1118
37. Eddahibi S, Raffestin B et al (1997) Treatment with 5-HT potentiates development of pulmonary hypertension in chronically hypoxic rats. Am J Physiol 272(3 Pt 2):H1173-H1181
38. Eddahibi S, Raffestin B et al (1998) Effect of dexfenfluramine treatment in rats exposed to acute and chronic hypoxia. Am J Respir Crit Care Med 157(4 Pt 1):1111-1119
39. Eddahibi S, Hanoun N et al (2000a) Attenuated hypoxic pulmonary hypertension in mice lacking the 5-hydroxytryptamine transporter gene. J Clin Invest 105(11):1555-1562
40. Eddahibi S, Humbert M et al (2000b) Imbalance between platelet vascular endothelial growth factor and platelet-derived growth factor in pulmonary hypertension. Effect of prostacyclin therapy. Am J Respir Crit Care Med 162(4 Pt 1):1493-1499
41. Eddahibi S, Humbert M et al (2001) Serotonin transporter overexpression is responsible for pulmonary artery smooth muscle hyperplasia in primary pulmonary hypertension. J Clin Invest 108(8):1141-1150
42. Eddahibi S, Humbert M et al (2002) Hyperplasia of pulmonary artery smooth muscle cells is causally related to overexpression of the serotonin transporter in primary pulmonary hypertension. Chest 121(3 Suppl):97S-98S
43. Eddahibi S, Guignabert C et al (2006) Cross talk between endothelial and smooth muscle cells in pulmonary hypertension: Critical role for serotonin-induced smooth muscle hyperplasia. Circulation 113(15):1857-1864
44. Fagan KA, Oka M et al (2004) Attenuation of acute hypoxic pulmonary vasoconstriction and hypoxic pulmonary hypertension in mice by inhibition of Rho-kinase. Am J Physiol Lung Cell Mol Physiol 287(4):L656-L664
45. Fischer P, Hilfiker-Kleiner D (2007) Survival pathways in hypertrophy and heart failure: The gp130-STAT axis. Basic Res Cardiol 102(5):393-411
46. Foletta VC, Lim MA et al (2003) Direct signaling by the BMP type II receptor via the cytoskeletal regulator LIMK1. J Cell Biol 162(6):1089-1098
47. Frishman WH, Huberfeld S et al (1995) Serotonin and serotonin antagonism in cardiovascular and non-cardiovascular disease. J Clin Pharmacol 35(6):541-572
48. Garcia-Cao I, Song MS et al (2012) Systemic elevation of PTEN induces a tumor-suppressive metabolic state. Cell 149(1):49-62
49. Gary-Bobo G, Houssaini A et al (2010) Effects of HIV protease inhibitors on progression of monocrotaline-and hypoxia-induced pulmonary hypertension in rats. Circulation 122(19):1937-1947
50. Geiger R, Berger RM et al (2000) Enhanced expression of vascular endothelial growth factor in pulmonary plexogenic arteriopathy due to congenital heart disease. J Pathol 191(2):202-207
51. George SJ, Johnson JL et al (2001) Plasmin-mediated fibroblast growth factor-2 mobilisation supports smooth muscle cell proliferation in human saphenous vein. J Vasc Res 38(5):492-501
52. George J, Sun J et al (2012) Transgenic expression of human matrix metalloproteinase-1 attenuates pulmonary arterial hypertension in mice. Clin Sci (Lond) 122(2):83-92
53. Gerasimovskaya EV, Tucker DA et al (2005) Activation of phosphatidylinositol 3-kinase, Akt, and mammalian target of rapamycin is necessary for hypoxia-induced pulmonary artery adventitial fibroblast proliferation. J Appl Physiol 98(2):722-731
54. Giannelli G, Falk-Marzillier J et al (1997) Induction of cell migration by matrix metalloprotease-2 cleavage of laminin-5. Science 277(5323):225-228
55. Gilboa L, Nohe A et al (2000) Bone morphogenetic protein receptor complexes on the surface of live cells: A new oligomerization mode for serine/threonine kinase receptors. Mol Biol Cell 11(3):1023-1035
56. Goda N, Kanai M (2012) Hypoxia-inducible factors and their roles in energy metabolism. Int J Hematol 95(5):457-463
57. Goncalves LM (1998) Fibroblast growth factor-mediated angiogenesis for the treatment of ischemia. Lessons learned from experimental models and early human experience. Rev Port Cardiol 17(Suppl 2):II11-II20
58. Grouf JL, Throm AM et al (2007) Differential effects of EGF and TGF-beta1 on fibroblast activity in fibrin-based tissue equivalents. Tissue Eng 13(4):799-807
59. Guignabert C (2011) Interplay between serotonin transporter signaling and voltage-gated potassium channel (Kv) 1.5 expression. In: Sulica R, Preston I (eds) Pulmonary hypertension-from bench research to clinical challenges. InTech Europe Rijeka, Croatia, pp 49-66
60. Guignabert C, Raffestin B et al (2005) Serotonin transporter inhibition prevents and reverses monocrotaline-induced pulmonary hypertension in rats. Circulation 111(21):2812-2819
61. Guignabert C, Izikki M et al (2006) Transgenic mice overexpressing the 5-hydroxytryptamine transporter gene in smooth muscle develop pulmonary hypertension. Circ Res 98(10):1323-1330
62. Guignabert C, Alvira CM et al (2009a) Tie2-mediated loss of peroxisome proliferator-activated receptor-gamma in mice causes PDGF receptor-beta- dependent pulmonary arterial muscularization. Am J Physiol Lung Cell Mol Physiol 297(6):L1082-L1090
63. Guignabert C, Tu L et al (2009b) Dichloroacetate treatment partially regresses established pulmonary hypertension in mice with SM22alpha-targeted overexpression of the serotonin transporter. FASEB J 23(12):4135-4147
64. Guilluy C, Sauzeau V et al (2005) Inhibition of RhoA/Rho kinase pathway is involved in the beneficial effect of sildenafil on pulmonary hypertension. Br J Pharmacol 146(7):1010-1018
65. Guilluy C, Rolli-Derkinderen M et al (2007) Transglutaminase-dependent RhoA activation and depletion by serotonin in vascular smooth muscle cells. J Biol Chem 282(5):2918-2928
66. Guilluy C, Eddahibi S et al (2009) RhoA and Rho kinase activation in human pulmonary hypertension: Role of 5-HT signaling. Am J Respir Crit Care Med 179(12):1151-1158
67. Guo L, Qiu Z et al (2012) The microRNA-328 regulates hypoxic pulmonary hypertension by targeting at insulin growth factor 1 receptor and L-type calcium channel-alpha1C. Hypertension 59(5):1006-1013
68. Gurtner HP (1985) Aminorex and pulmonary hypertension. A review. Cor Vasa 27(2-3):160-171
69. He H, Venema VJ et al (1999) Vascular endothelial growth factor signals endothelial cell production of nitric oxide and prostacyclin through flk-1/KDR activation of c-Src. J Biol Chem 274(35):25130-25135
70. Herrlich A, Daub H et al (1998) Ligand-independent activation of platelet-derived growth factor receptor is a necessary intermediate in lysophosphatidic, acid-stimulated mitogenic activity in L cells. Proc Natl Acad Sci USA 95(15):8985-8990
71. Herve P, Drouet L et al (1990) Primary pulmonary hypertension in a patient with a familial platelet storage pool disease: Role of serotonin. Am J Med 89(1):117-120
72. Herve P, Launay JM et al (1995) Increased plasma serotonin in primary pulmonary hypertension. Am J Med 99(3):249-254
73. Hiramine K, Sata N et al (2011) Hepatocyte growth factor improves the survival of rats with pulmonary arterial hypertension via the amelioration of pulmonary hemodynamics. Int J Mol Med 27(4):497-502
74. Hironaka E, Hongo M et al (2003) Serotonin receptor antagonist inhibits monocrotaline-induced pulmonary hypertension and prolongs survival in rats. Cardiovasc Res 60(3):692-699
75. Hirose S, Hosoda Y et al (2000) Expression of vascular endothelial growth factor and its receptors correlates closely with formation of the plexiform lesion in human pulmonary hypertension. Pathol Int 50(6):472-479
76. Huber K, Beckmann R et al (1994) Fibrinogen, t-PA, and PAI-1 plasma levels in patients with pulmonary hypertension. Am J Respir Crit Care Med 150(4):929-933
77. Huertas A, Tu L et al (2012) Leptin and regulatory T lymphocytes in idiopathic pulmonary arterial hypertension. Eur Respir J 40(4):895-904
78. Humbert M, Monti G et al (1995) Increased interleukin-1 and interleukin-6 serum concentrations in severe primary pulmonary hypertension. Am J Respir Crit Care Med 151(5):1628-1631
79. Humbert M, Morrell NW et al (2004) Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol 43(12 Suppl S):13S-24S
80. Ieda M, Fukuda K et al (2004) Endothelin-1 regulates cardiac sympathetic innervation in the rodent heart by controlling nerve growth factor expression. J Clin Invest 113(6):876-884
81. Ilkiw R, Todorovich-Hunter L et al (1989) SC-39026, a serine elastase inhibitor, prevents muscularization of peripheral arteries, suggesting a mechanism of monocrotaline-induced pulmonary hypertension in rats. Circ Res 64(4):814-825
82. Izikki M, Hanoun N et al (2007) Tryptophan hydroxylase 1 knockout and tryptophan hydroxylase 2 polymorphism: Effects on hypoxic pulmonary hypertension in mice. Am J Physiol Lung Cell Mol Physiol 293(4):L1045-L1052
83. Izikki M, Guignabert C et al (2009) Endothelial-derived FGF2 contributes to the progression of pulmonary hypertension in humans and rodents. J Clin Invest 119(3):512-523
84. Jiang GC, Tidwell K et al (2007) Neurotoxic potential of depleted uranium effects in primary cortical neuron cultures and in Caenorhabditis elegans. Toxicol Sci 99(2):553-565
85. Jones PL, Rabinovitch M (1996) Tenascin-C is induced with progressive pulmonary vascular disease in rats and is functionally related to increased smooth muscle cell proliferation. Circ Res 79(6):1131-1142
86. Jones PL, Cowan KN et al (1997a) Tenascin-C, proliferation and subendothelial fibronectin in progressive pulmonary vascular disease. Am J Pathol 150(4):1349-1360
87. Jones PL, Crack J et al (1997b) Regulation of tenascin-C, a vascular smooth muscle cell survival factor that interacts with the alpha v beta 3 integrin to promote epidermal growth factor receptor phosphorylation and growth. J Cell Biol 139(1):279-293
88. Jones PL, Jones FS et al (1999) Induction of vascular smooth muscle cell tenascin-C gene expression by denatured type I collagen is dependent upon a beta3 integrin-mediated mitogen-activated protein kinase pathway and a 122-base pair promoter element. J Cell Sci 112(Pt 4):435-445
89. Kasahara Y, Tuder RM et al (2000) Inhibition of VEGF receptors causes lung cell apoptosis and emphysema. J Clin Invest 106(11):1311-1319
90. Katta S, Vadapalli S et al (2008) t-plasminogen activator inhibitor-1 polymorphism in idiopathic pulmonary arterial hypertension. Indian J Hum Genet 14(2):37-40
91. Keegan A, Morecroft I et al (2001) Contribution of the 5-HT(1B) receptor to hypoxia-induced pulmonary hypertension: Converging evidence using 5-HT(1B)-receptor knockout mice and the 5-HT(1B/1D)-receptor antagonist GR127935. Circ Res 89(12):1231-1239
92. Kelvin DJ, Simard G et al (1989) FGF and EGF act synergistically to induce proliferation in BC3H1 myoblasts. J Cell Physiol 138(2):267-272
93. Kereveur A, Callebert J et al (2000) High plasma serotonin levels in primary pulmonary hypertension. Effect of long-term epoprostenol (prostacyclin) therapy. Arterioscler Thromb Vasc Biol 20(10):2233-2239
94. Kherbeck N, Tamby MC et al (2013) The role of inflammation and autoimmunity in the pathophysiology of pulmonary arterial hypertension. Clin Rev Allergy Immunol 44(1):31-38
95. Kim YM, Haghighat L et al (2011) Neutrophil elastase is produced by pulmonary artery smooth muscle cells and is linked to neointimal lesions. Am J Pathol 179(3):1560-1572
96. Kimura K, Ieda M et al (2007) Cardiac sympathetic rejuvenation: A link between nerve function and cardiac hypertrophy. Circ Res 100(12):1755-1764
97. Kouri FM, Queisser MA et al (2008) Plasminogen activator inhibitor type 1 inhibits smooth muscle cell proliferation in pulmonary arterial hypertension. Int J Biochem Cell Biol 40(9):1872-1882
98. Krymskaya VP, Goncharova EA (2009) PI3K/mTORC1 activation in hamartoma syndromes: Therapeutic prospects. Cell Cycle 8(3):403-413
99. Krymskaya VP, Snow J et al (2011) mTOR is required for pulmonary arterial vascular smooth muscle cell proliferation under chronic hypoxia. FASEB J 25(6):1922-1933
100. Kwapiszewska G, Markart P et al (2012) PAR-2 inhibition reverses experimental pulmonary hypertension. Circ Res 110(9):1179-1191
101. Laplante M, Sabatini DM (2009) mTOR signaling at a glance. J Cell Sci 122(Pt 20):3589-3594
102. Laudi S, Steudel W et al (2007) Comparison of lung proteome profiles in two rodent models of pulmonary arterial hypertension. Proteomics 7(14):2469-2478
103. Launay JM, Herve P et al (2002) Function of the serotonin 5-hydroxytryptamine 2B receptor in pulmonary hypertension. Nat Med 8(10):1129-1135
104. Launay JM, Schneider B et al (2006) Serotonin transport and serotonin transporter-mediated antidepressant recognition are controlled by 5-HT2B receptor signaling in serotonergic neuronal cells. FASEB J 20(11):1843-1854
105. Lawrie A, Spiekerkoetter E et al (2005) Interdependent serotonin transporter and receptor pathways regulate S100A4/Mts1, a gene associated with pulmonary vascular disease. Circ Res 97(3):227-235
106. Le Cras TD, Hardie WD et al (2003) Disrupted pulmonary vascular development and pulmonary hypertension in transgenic mice overexpressing transforming growth factor-alpha. Am J Physiol Lung Cell Mol Physiol 285(5):L1046-L1054
107. Lee YS, Byun J et al (2005) Monocrotaline-induced pulmonary hypertension correlates with upregulation of connective tissue growth factor expression in the lung. Exp Mol Med 37(1):27-35
108. Lepetit H, Eddahibi S et al (2005) Smooth muscle cell matrix metalloproteinases in idiopathic pulmonary arterial hypertension. Eur Respir J 25(5):834-842
109. Li P, Oparil S et al (2003) Fibroblast growth factor mediates hypoxia-induced endothelin-a receptor expression in lung artery smooth muscle cells. J Appl Physiol 95(2):643-651, discussion 863
110. Long L, MacLean MR et al (2006) Serotonin increases susceptibility to pulmonary hypertension in BMPR2-deficient mice. Circ Res 98(6):818-827
111. Loogen F, Worth H et al (1985) Long-term follow-up of pulmonary hypertension in patients with and without anorectic drug intake. Cor Vasa 27(2-3):111-124
112. Louzier V, Raffestin B et al (2003) Role of VEGF-B in the lung during development of chronic hypoxic pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 284(6):L926-L937
113. Ma W, Han W et al (2011) Calpain mediates pulmonary vascular remodeling in rodent models of pulmonary hypertension, and its inhibition attenuates pathologic features of disease. J Clin Invest 121(11):4548-4566
114. MacLean MR, Deuchar GA et al (2004) Overexpression of the 5-hydroxytryptamine transporter gene: Effect on pulmonary hemodynamics and hypoxia-induced pulmonary hypertension. Circulation 109(17):2150-2155
115. Marcos E, Adnot S et al (2003) Serotonin transporter inhibitors protect against hypoxic pulmonary hypertension. Am J Respir Crit Care Med 168(4):487-493
116. Marcos E, Fadel E et al (2004) Serotonin-induced smooth muscle hyperplasia in various forms of human pulmonary hypertension. Circ Res 94(9):1263-1270
117. Marcos E, Fadel E et al (2005) Serotonin transporter and receptors in various forms of human pulmonary hypertension. Chest 128(6 Suppl):552S-553S
118. Maruyama K, Ye CL et al (1991) Chronic hypoxic pulmonary hypertension in rats and increased elastolytic activity. Am J Physiol 261(6 Pt 2):H1716-H1726
119. Masri FA, Xu W et al (2007) Hyperproliferative apoptosis-resistant endothelial cells in idiopathic pulmonary arterial hypertension. Am J Physiol Lung Cell Mol Physiol 293(3):L548-L554
120. Mathew R, Huang J et al (2004) Disruption of endothelial-cell caveolin-1alpha/raft scaffolding during development of monocrotaline-induced pulmonary hypertension. Circulation 110 (11):1499-1506
121. Matsunaga S, Okigaki M et al (2009) Endothelium-targeted overexpression of constitutively active FGF receptor induces cardioprotection in mice myocardial infarction. J Mol Cell Cardiol 46(5):663-673
122. McMurtry MS, Bonnet S et al (2004) Dichloroacetate prevents and reverses pulmonary hypertension by inducing pulmonary artery smooth muscle cell apoptosis. Circ Res 95(8):830-840
123. Merklinger SL, Jones PL et al (2005) Epidermal growth factor receptor blockade mediates smooth muscle cell apoptosis and improves survival in rats with pulmonary hypertension. Circulation 112(3):423-431
124. Michelakis ED, McMurtry MS et al (2002) Dichloroacetate, a metabolic modulator, prevents and reverses chronic hypoxic pulmonary hypertension in rats: Role of increased expression and activity of voltage-gated potassium channels. Circulation 105(2):244-250
125. Mitani Y, UedaMet al (1999) Mast cell chymase in pulmonary hypertension. Thorax 54(1):88-90
126. Morecroft I, Heeley RP et al (1999) 5-hydroxytryptamine receptors mediating contraction in human small muscular pulmonary arteries: Importance of the 5-HT1B receptor. Br J Pharmacol 128(3):730-734
127. Morecroft I, Loughlin L et al (2005) Functional interactions between 5-hydroxytryptamine receptors and the serotonin transporter in pulmonary arteries. J Pharmacol Exp Ther 313(2):539-548
128. Morrell NW, Adnot S et al (2009) Cellular and molecular basis of pulmonary arterial hypertension. J Am Coll Cardiol 54(1 Suppl):S20-S31
129. Murillo MM, del Castillo G et al (2005) Involvement of EGF receptor and c-Src in the survival signals induced by TGF-beta1 in hepatocytes. Oncogene 24(28):4580-4587
130. Nagaoka T, Morio Y et al (2004) Rho/Rho kinase signaling mediates increased basal pulmonary vascular tone in chronically hypoxic rats. Am J Physiol Lung Cell Mol Physiol 287(4): L665-L672
131. Nagaoka T, Fagan KA et al (2005) Inhaled Rho kinase inhibitors are potent and selective vasodilators in rat pulmonary hypertension. Am J Respir Crit Care Med 171(5):494-499
132. Nagy JA, Dvorak AM et al (2012) Vascular hyperpermeability, angiogenesis, and stroma generation. Cold Spring Harb Perspect Med 2(2):a006544
133. Nakagawa O, Fujisawa K et al (1996) ROCK-I and ROCK-II, two isoforms of Rho-associated coiled-coil forming protein serine/threonine kinase in mice. FEBS Lett 392(2):189-193
134. Nasim MT, Ogo T et al (2012) BMPR-II deficiency elicits pro-proliferative and anti-apoptotic responses through the activation of TGFbeta-TAK1-MAPK pathways in PAH. Hum Mol Genet 21(11):2548-2558
135. Natali D, Girerd B et al (2011) Pulmonary arterial hypertension in a patient with Cowden syndrome and anorexigen exposure. Chest 140(4):1066-1068
136. Nilsson O, Ericson LE et al (1985) Subcellular localization of serotonin immunoreactivity in rat enterochromaffin cells. Histochemistry 82(4):351-355
137. Nishimaki T, Aotsuka S et al (1999) Immunological analysis of pulmonary hypertension in connective tissue diseases. J Rheumatol 26(11):2357-2362
138. O'Callaghan DS, Savale L et al (2011) Treatment of pulmonary arterial hypertension with targeted therapies. Nat Rev Cardiol 8(9):526-538
139. Ogawa A, Firth AL et al (2012) PDGF enhances store-operated Ca2+ entry by upregulating STIM1/Orai1 via activation of Akt/mTOR in human pulmonary arterial smooth muscle cells. Am J Physiol Cell Physiol 302(2):C405-C411
140. Ono M, Sawa Y et al (2004a) Gene transfer of hepatocyte growth factor with prostacyclin synthase in severe pulmonary hypertension of rats. Eur J Cardiothorac Surg 26(6):1092-1097
141. Ono M, Sawa Y et al (2004b) Hepatocyte growth factor suppresses vascular medial hyperplasia and matrix accumulation in advanced pulmonary hypertension of rats. Circulation 110 (18):2896-2902
142. Park JS, Kim JY et al (2000) Epidermal growth factor (EGF) antagonizes transforming growth factor (TGF)-beta1-induced collagen lattice contraction by human skin fibroblasts. Biol Pharm Bull 23(12):1517-1520
143. Partovian C, Adnot S et al (1998) Heart and lung VEGF mRNA expression in rats with monocrotaline-or hypoxia-induced pulmonary hypertension. Am J Physiol 275(6 Pt 2): H1948-H1956
144. Partovian C, Adnot S et al (2000) Adenovirus-mediated lung vascular endothelial growth factor overexpression protects against hypoxic pulmonary hypertension in rats. Am J Respir Cell Mol Biol 23(6):762-771
145. Paulin R, Courboulin A et al (2011a) Signal transducers and activators of transcription-3/pim1 axis plays a critical role in the pathogenesis of human pulmonary arterial hypertension. Circulation 123(11):1205-1215
146. Paulin R, Meloche J et al (2011b) Dehydroepiandrosterone inhibits the Src/STAT3 constitutive activation in pulmonary arterial hypertension. Am J Physiol Heart Circ Physiol 301(5): H1798-H1809
147. Pendergrass SA, Hayes E et al (2010) Limited systemic sclerosis patients with pulmonary arterial hypertension show biomarkers of inflammation and vascular injury. PLoS One 5(8):e12106
148. Perros F, Montani D et al (2008) Platelet-derived growth factor expression and function in idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med 178(1):81-88
149. Perros F, Dorfmuller P et al (2012) Pulmonary lymphoid neogenesis in idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med 185(3):311-321
150. Price LC, Wort SJ et al (2012) Inflammation in pulmonary arterial hypertension. Chest 141 (1):210-221
151. Puzio-Kuter AM (2011) The role of p53 in metabolic regulation. Genes Cancer 2(4):385-391
152. Quinn TP, Schlueter M et al (2002) Cyclic mechanical stretch induces VEGF and FGF-2 expression in pulmonary vascular smooth muscle cells. Am J Physiol Lung Cell Mol Physiol 282(5):L897-L903
153. Rabinovitch M (1999) EVE and beyond, retro and prospective insights. Am J Physiol 277(1 Pt 1): L5-L12
154. Rabinovitch M (2001) Pathobiology of pulmonary hypertension. Extracellular matrix. Clin Chest Med 22(3):433-449, viii
155. Rabinovitch M (2005) Cellular and molecular pathobiology of pulmonary hypertension conference summary. Chest 128(6 Suppl):642S-646S
156. Ravi Y, Selvendiran K et al (2011) Dysregulation of PTEN in cardiopulmonary vascular remodeling induced by pulmonary hypertension. Cell Biochem Biophys. doi:10.1007/s12013-011-9332-z
157. Ray L, Mathieu M et al (2008) Early increase in pulmonary vascular reactivity with overexpression of endothelin-1 and vascular endothelial growth factor in canine experimental heart failure. Exp Physiol 93(3):434-442
158. Ren W, Watts SW et al (2011) Serotonin transporter interacts with the PDGFbeta receptor in PDGF-BB-induced signaling and mitogenesis in pulmonary artery smooth muscle cells. Am J Physiol Lung Cell Mol Physiol 300(3):L486-L497
159. Reynolds AM, Holmes MD et al (2012) Targeted gene delivery of BMPR2 attenuates pulmonary hypertension. Eur Respir J 39(2):329-343
160. Rondelet B, Kerbaul F et al (2003) Bosentan for the prevention of overcirculation-induced experimental pulmonary arterial hypertension. Circulation 107(9):1329-1335
161. Saito Y, Berk BC (2001) Transactivation: A novel signaling pathway from angiotensin II to tyrosine kinase receptors. J Mol Cell Cardiol 33(1):3-7
162. Sands M, Howell K et al (2011) Placenta growth factor and vascular endothelial growth factor B expression in the hypoxic lung. Respir Res 12:17
163. Sato K, Webb S et al (1992) Factors influencing the idiopathic development of pulmonary hypertension in the fawn hooded rat. Am Rev Respir Dis 145(4 Pt 1):793-797
164. Savale L, Tu L et al (2009) Impact of interleukin-6 on hypoxia-induced pulmonary hypertension and lung inflammation in mice. Respir Res 10:6
165. Schermuly RT, Dony E et al (2005) Reversal of experimental pulmonary hypertension by PDGF inhibition. J Clin Invest 115(10):2811-2821
166. Shang M, Koshikawa N et al (2001) The LG3 module of laminin-5 harbors a binding site for integrin alpha3beta1 that promotes cell adhesion, spreading, and migration. J Biol Chem 276(35):33045-33053
167. Soon E, Holmes AM et al (2010) Elevated levels of inflammatory cytokines predict survival in idiopathic and familial pulmonary arterial hypertension. Circulation 122(9):920-927
168. Steiner MK, Syrkina OL et al (2009) Interleukin-6 overexpression induces pulmonary hypertension. Circ Res 104(2):236-244, 228p following 244
169. Sullivan CC, Du L et al (2003) Induction of pulmonary hypertension by an angiopoietin 1/TIE2/serotonin pathway. Proc Natl Acad Sci USA 100(21):12331-12336
170. Sundaram N, Tailor A et al (2010) High levels of placenta growth factor in sickle cell disease promote pulmonary hypertension. Blood 116(1):109-112
171. Sutendra G, Bonnet S et al (2010) Fatty acid oxidation and malonyl-CoA decarboxylase in the vascular remodeling of pulmonary hypertension. Sci Transl Med 2(44):44ra58
172. Takahashi H, Goto N et al (2006) Downregulation of type II bone morphogenetic protein receptor in hypoxic pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 290(3):L450-L458
173. Tamby MC, Chanseaud Y et al (2005) Anti-endothelial cell antibodies in idiopathic and systemic sclerosis associated pulmonary arterial hypertension. Thorax 60(9):765-772
174. Tamosiuniene R, Tian W et al (2011) Regulatory T cells limit vascular endothelial injury and prevent pulmonary hypertension. Circ Res 109(8):867-879
175. Tanabe Y, Saito M et al (2000) Mechanical stretch augments PDGF receptor beta expression and protein tyrosine phosphorylation in pulmonary artery tissue and smooth muscle cells. Mol Cell Biochem 215(1-2):103-113
176. Taraseviciene-Stewart L, Kasahara Y et al (2001) Inhibition of the VEGF receptor 2 combined with chronic hypoxia causes cell death-dependent pulmonary endothelial cell proliferation and severe pulmonary hypertension. FASEB J 15(2):427-438
177. Teichert-Kuliszewska K, Kutryk MJ et al (2006) Bone morphogenetic protein receptor-2 signaling promotes pulmonary arterial endothelial cell survival: Implications for loss-of-function mutations in the pathogenesis of pulmonary hypertension. Circ Res 98(2):209-217
178. Terrier B, Tamby MC et al (2008) Identification of target antigens of antifibroblast antibodies in pulmonary arterial hypertension. Am J Respir Crit Care Med 177(10):1128-1134
179. Thompson K, Rabinovitch M (1996) Exogenous leukocyte and endogenous elastases can mediate mitogenic activity in pulmonary artery smooth muscle cells by release of extracellular-matrix bound basic fibroblast growth factor. J Cell Physiol 166(3):495-505
180. Tian J, Smith A et al (2009) Effect of PPARgamma inhibition on pulmonary
181. Tu L, Dewachter L et al (2011) Autocrine fibroblast growth factor-2 signaling contributes to altered endothelial phenotype in pulmonary hypertension. Am J Respir Cell Mol Biol 45(2):311-322
182. Tu L, de Man FS et al (2012) A critical role for p130Cas in the progression of pulmonary hypertension in humans and rodent. Am J Respir Crit Care Med 186(7):666-676
183. Tuder RM, Chacon M et al (2001) Expression of angiogenesis-related molecules in plexiform lesions in severe pulmonary hypertension: Evidence for a process of disordered angiogenesis. J Pathol 195(3):367-374
184. Uttamsingh S, Bao X et al (2008) Synergistic effect between EGF and TGF-beta1 in inducing oncogenic properties of intestinal epithelial cells. Oncogene 27(18):2626-2634
185. Vanhoutte PM (1991) Platelet-derived serotonin, the endothelium, and cardiovascular disease. J Cardiovasc Pharmacol 17(Suppl 5):S6-S12
186. Vieillard-Baron A, Frisdal E et al (2000) Inhibition of matrix metalloproteinases by lung TIMP-1 gene transfer or doxycycline aggravates pulmonary hypertension in rats. Circ Res 87(5):418-425
187. Vieillard-Baron A, Frisdal E et al (2003) Inhibition of matrix metalloproteinases by lung TIMP-1 gene transfer limits monocrotaline-induced pulmonary vascular remodeling in rats. Hum Gene Ther 14(9):861-869
188. Voelkel NF, Vandivier RW et al (2006) Vascular endothelial growth factor in the lung. Am J Physiol Lung Cell Mol Physiol 290(2):L209-L221
189. Wang Y, Han DD et al (2011) Downregulation of osteopontin is associated with fluoxetine amelioration of monocrotaline-induced pulmonary inflammation and vascular remodelling. Clin Exp Pharmacol Physiol 38(6):365-372
190. Wedgwood S, Devol JM et al (2007) Fibroblast growth factor-2 expression is altered in lambs with increased pulmonary blood flow and pulmonary hypertension. Pediatr Res 61(1):32-36
191. Wei L, Warburton R et al (2012) Serotonylated fibronectin is elevated in pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 302(12):L1273-L1279
192. Wheeler-Jones C, Abu-Ghazaleh R et al (1997) Vascular endothelial growth factor stimulates prostacyclin production and activation of cytosolic phospholipase A2 in endothelial cells via p42/p44 mitogen-activated protein kinase. FEBS Lett 420(1):28-32
193. Wullschleger S, Loewith R et al (2006) TOR signaling in growth and metabolism. Cell 124(3):471-484
194. Xu J, Rodriguez D et al (2001) Proteolytic exposure of a cryptic site within collagen type IV is required for angiogenesis and tumor growth in vivo. J Cell Biol 154(5):1069-1079
195. Xu W, Koeck T et al (2007) Alterations of cellular bioenergetics in pulmonary artery endothelial cells. Proc Natl Acad Sci USA 104(4):1342-1347
196. Yamboliev IA, Gerthoffer WT (2001) Modulatory role of ERK MAPK-caldesmon pathway in PDGF-stimulated migration of cultured pulmonary artery SMCs. Am J Physiol Cell Physiol 280(6):C1680-C1688
197. Yang X, Long L et al (2005) Dysfunctional Smad signaling contributes to abnormal smooth muscle cell proliferation in familial pulmonary arterial hypertension. Circ Res 96 (10):1053-1063
198. Zaidi SH, You XM et al (2002) Overexpression of the serine elastase inhibitor elafin protects transgenic mice from hypoxic pulmonary hypertension. Circulation 105(4):516-521
199. Zhai FG, Zhang XH et al (2009) Fluoxetine protects against monocrotaline-induced pulmonary arterial hypertension: Potential roles of induction of apoptosis and upregulation of Kv1.5 channels in rats. Clin Exp Pharmacol Physiol 36(8):850-856
200. Zhu SP, Mao ZF et al (2009) Continuous fluoxetine administration prevents recurrence of pulmonary arterial hypertension and prolongs survival in rats. Clin Exp Pharmacol Physiol 36(8):e1-e5